Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC with Nab-paclitaxel in Pancreatic Adenocarcinoma
NCT07253662Phase 1Recruiting
- Sponsor
- Northwell Health
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Northwell Health. Primary endpoint: Safety and tolerability assessed by CTCAE v5.0 at 2 years. Started Jan 2026; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07253662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253662.